Current Therapeutic Delivery Approaches Using Nanocarriers for the Treatment of Tuberculosis Disease.

[1]  Junghyun Cho,et al.  Photocatalytic TiO2 nanomaterials as potential antimicrobial and antiviral agents: Scope against blocking the SARS-COV-2 spread , 2021, Micro and Nano Engineering.

[2]  S. Kaufmann.  Vaccine Development Against Tuberculosis Over the Last 140 Years: Failure as Part of Success , 2021, Frontiers in Microbiology.

[3]  M. Cucchiarini,et al.  Design of Mannose-Coated Rifampicin nanoparticles modulating the immune response and Rifampicin induced hepatotoxicity with improved oral drug delivery , 2021 .

[4]  Ting-ting Xu,et al.  COVID-19 and Tuberculosis Coinfection: An Overview of Case Reports/Case Series and Meta-Analysis , 2021, Frontiers in Medicine.

[5]  K. Dooley,et al.  Diabetes Mellitus and Tuberculosis Treatment Outcomes in Pune, India , 2021, Open forum infectious diseases.

[6]  Qiang Li,et al.  The Value of the inhA Mutation Detection in Predicting Ethionamide Resistance Using Melting Curve Technology , 2021, Infection and drug resistance.

[7]  M. Young,et al.  Urgent global action is needed on multi drug-resistant tuberculosis (MDR-TB) – can small cone moxa contribute to a global response? , 2020 .

[8]  V. Goyal,et al.  Spinal Tuberculosis Treatment: An Enduring Bone of Contention , 2020, Annals of Indian Academy of Neurology.

[9]  Xueqiong Wu,et al.  Effects of Mycobacterium vaccae vaccine in a mouse model of tuberculosis: protective action and differentially expressed genes , 2020, Military Medical Research.

[10]  T. Prasad,et al.  Recent updates on drug resistance in Mycobacterium tuberculosis , 2020, Journal of applied microbiology.

[11]  Kalpesh Vaghasiya,et al.  Dynamic mucus penetrating microspheres for efficient pulmonary delivery and enhanced efficacy of host defence peptide (HDP) in experimental tuberculosis. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[12]  Biao Xu,et al.  Improved treatment outcome of multidrug-resistant tuberculosis with the use of a rapid molecular test to detect drug resistance in China. , 2020, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[13]  A. Gori,et al.  Celebrating TB day at the time of COVID-19 , 2020, European Respiratory Journal.

[14]  M. Matsumoto,et al.  OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor , 2020, Antimicrobial Agents and Chemotherapy.

[15]  V. Makarov,et al.  Development of Macozinone for TB treatment: An Update , 2020, Applied Sciences.

[16]  R. Hurtado,et al.  Challenges and controversies in the treatment of spinal tuberculosis , 2020, Journal of clinical tuberculosis and other mycobacterial diseases.

[17]  M. Bhargava,et al.  Tuberculosis deaths are predictable and preventable: Comprehensive assessment and clinical care is the key , 2020, Journal of clinical tuberculosis and other mycobacterial diseases.

[18]  Chaolin Huang,et al.  Validating the surgical indication value of the LTB-S classification system for Drug-Resistant Tuberculosis. , 2020, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[19]  G. Grüber.  Introduction: Novel insights into TB research and drug discovery. , 2020, Progress in biophysics and molecular biology.

[20]  E. Kurbatova,et al.  Isoniazid- and Rifampin-Resistance Mutations Associated with Resistance to Second-line Drugs and with Sputum Culture Conversion. , 2020, The Journal of infectious diseases.

[21]  D. Visca,et al.  Rehabilitation, optimized nutritional care and boosting host internal milieu to improve long-term treatment outcomes in TB patients. , 2020, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[22]  L. Chiarelli,et al.  Promiscuous Targets for Antitubercular Drug Discovery: The Paradigm of DprE1 and MmpL3 , 2020, Applied Sciences.

[23]  D. Rawat,et al.  An overview of new antitubercular drugs, drug candidates, and their targets , 2020, Medicinal research reviews.

[24]  S. Kudoh,et al.  Treatment of multidrug-resistant pulmonary tuberculosis with delamanid based on Japanese guideline recommendations. , 2019, Respiratory investigation.

[25]  L. Abu-Raddad,et al.  Epidemiological impact of targeted interventions for people with diabetes mellitus on tuberculosis transmission in India: Modelling based predictions. , 2019, Epidemics.

[26]  M. Demoitié,et al.  Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis. , 2019, The New England journal of medicine.

[27]  Yan-bin Zhang,et al.  Efficacy and safety of concurrent anti-tuberculosis treatment and chemotherapy in lung cancer patients with co-existent tuberculosis , 2019, Annals of translational medicine.

[28]  D. Chiappetta,et al.  Pulmonary delivery of rifampicin-loaded soluplus micelles against Mycobacterium tuberculosis , 2019, Journal of Drug Delivery Science and Technology.

[29]  R. Hayeshi,et al.  Spray-Dried, Nanoencapsulated, Multi-Drug Anti-Tuberculosis Therapy Aimed at Once Weekly Administration for the Duration of Treatment , 2019, Nanomaterials.

[30]  X. Li,et al.  Detection of novel mutations associated with independent resistance and cross-resistance to isoniazid and prothionamide in Mycobacterium tuberculosis clinical isolates. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[31]  Polly Nula,et al.  Tuberculosis in North-East India: patient profile and treatment outcome of patient attending RNTCP , 2019, International Journal Of Community Medicine And Public Health.

[32]  K. Bhaumik,et al.  Mechanisms of the effectiveness of lipid nanoparticle formulations loaded with anti-tubercular drugs combinations toward overcoming drug bioavailability in tuberculosis , 2019, Journal of drug targeting (Print).

[33]  H. Kornfeld,et al.  Tuberculosis and diabetes: from bench to bedside and back. , 2019, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[34]  A. Hussain,et al.  Nanomedicines as Drug Delivery Carriers of Anti-Tubercular Drugs: From Pathogenesis to Infection Control , 2019, Current drug delivery.

[35]  A. M. Rosa da Costa,et al.  Inhalable chitosan microparticles for simultaneous delivery of isoniazid and rifabutin in lung tuberculosis treatment , 2019, Drug development and industrial pharmacy.

[36]  B. Restrepo,et al.  The re-emerging association between tuberculosis and diabetes: Lessons from past centuries. , 2019, Tuberculosis.

[37]  P. Liu,et al.  A thermo‐responsive and self‐healing liposome‐in‐hydrogel system as an antitubercular drug carrier for localized bone tuberculosis therapy , 2019, International journal of pharmaceutics.

[38]  C. Locht,et al.  Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis , 2019, ACS nano.

[39]  A. Danckaert,et al.  Tri-mannose grafting of chitosan nanocarriers remodels the macrophage response to bacterial infection , 2019, Journal of Nanobiotechnology.

[40]  M. Tameris,et al.  Dose Optimization of H56:IC31 Vaccine for Tuberculosis‐Endemic Populations. A Double‐Blind, Placebo‐controlled, Dose‐Selection Trial , 2019, American journal of respiratory and critical care medicine.

[41]  C. Emiliani,et al.  Biocompatible Polymer Nanoparticles for Drug Delivery Applications in Cancer and Neurodegenerative Disorder Therapies , 2019, Journal of functional biomaterials.

[42]  A. Urtti,et al.  Enhanced Delivery of 4-Thioureidoiminomethylpyridinium Perchlorate in Tuberculosis Models with IgG Functionalized Poly(Lactic Acid)-Based Particles , 2018, Pharmaceutics.

[43]  Alimuddin Zumla,et al.  The historic and unprecedented United Nations General Assembly High Level Meeting on Tuberculosis (UNGA-HLM-TB)-'United to End TB: An Urgent Global Response to a Global Epidemic'. , 2018, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[44]  W. Yam,et al.  Drug resistance mechanisms and drug susceptibility testing for tuberculosis , 2018, Respirology.

[45]  Deepa Thomas,et al.  Synthesis and in vitro evaluation of alginate-cellulose nanocrystal hybrid nanoparticles for the controlled oral delivery of rifampicin , 2018, Journal of Drug Delivery Science and Technology.

[46]  A. Chaiprasert,et al.  Overexpression of eis without a mutation in promoter region of amikacin- and kanamycin-resistant Mycobacterium tuberculosis clinical strain , 2018, Annals of clinical microbiology and antimicrobials.

[47]  Yongge Liu,et al.  Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB). , 2018, Tuberculosis.

[48]  Y. Pang,et al.  Comparison of In Vitro Activity and MIC Distributions between the Novel Oxazolidinone Delpazolid and Linezolid against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis in China , 2018, Antimicrobial Agents and Chemotherapy.

[49]  A. Bañuls,et al.  Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[50]  B. Sarmento,et al.  Mannose‐functionalized solid lipid nanoparticles are effective in targeting alveolar macrophages , 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[51]  D. Jary,et al.  New active formulations against M. tuberculosis: Bedaquiline encapsulation in lipid nanoparticles and chitosan nanocapsules , 2017 .

[52]  K. Becker,et al.  Molecular Mechanisms of Intrinsic Streptomycin Resistance in Mycobacterium abscessus , 2017, Antimicrobial Agents and Chemotherapy.

[53]  Priscilla A T Pereira,et al.  Microparticles prepared with 50-190kDa chitosan as promising non-toxic carriers for pulmonary delivery of isoniazid. , 2017, Carbohydrate polymers.

[54]  V. Pillay,et al.  Development of respirable rifampicin-loaded nano-lipomer composites by microemulsion-spray drying for pulmonary delivery , 2017 .

[55]  David Barros,et al.  Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656). , 2017, Journal of medicinal chemistry.

[56]  S. Kaufmann,et al.  The Recombinant Bacille Calmette–Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing , 2017, Front. Immunol..

[57]  Y. Pang,et al.  Rifabutin Resistance Associated with Double Mutations in rpoB Gene in Mycobacterium tuberculosis Isolates , 2017, Front. Microbiol..

[58]  A. Martin,et al.  Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis , 2017, European Respiratory Journal.

[59]  P. Saha,et al.  Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial , 2017, Scientific Reports.

[60]  Rajendran Amarnath Praphakar,et al.  Development of extended-voyaging anti-oxidant Linked Amphiphilic Polymeric Nanomicelles for Anti-Tuberculosis Drug Delivery. , 2017, International journal of pharmaceutics.

[61]  Prabagaran Narayanasamy,et al.  Gallium nanoparticles facilitate phagosome maturation and inhibit growth of virulent Mycobacterium tuberculosis in macrophages , 2017, PloS one.

[62]  M. Drancourt,et al.  Themed Issue : Resurrection of old antibiotics Old antibiotics for emerging multidrug-resistant / extensively drug-resistant tuberculosis ( MDR / XDR-TB ) , 2017 .

[63]  E. V. van Rikxoort,et al.  Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized Trial , 2017, American journal of respiratory and critical care medicine.

[64]  Neeraj Kumar,et al.  Lipid Nanocarrier-Mediated Drug Delivery System to Enhance the Oral Bioavailability of Rifabutin , 2017, AAPS PharmSciTech.

[65]  Hamid Najminejad,et al.  Development of an effective delivery system for intranasal immunization against Mycobacterium tuberculosis ESAT-6 antigen , 2017, Artificial cells, nanomedicine, and biotechnology.

[66]  M. Yousefi,et al.  Linezolid: a promising option in the treatment of Gram-positives , 2017, The Journal of antimicrobial chemotherapy.

[67]  D. Anh,et al.  Molecular analysis of pyrazinamide resistance in Mycobacterium tuberculosis in Vietnam highlights the high rate of pyrazinamide resistance-associated mutations in clinical isolates , 2017, Emerging microbes & infections.

[68]  K. Sadasivuni,et al.  Targeted delivery of rifampicin to tuberculosis-infected macrophages: design, in-vitro, and in-vivo performance of rifampicin-loaded poly(ester amide)s nanocarriers. , 2016, International journal of pharmaceutics.

[69]  A. Jirgensons,et al.  Evaluation of the characteristics of leucyl-tRNA synthetase (LeuRS) inhibitor AN3365 in combination with different antibiotic classes , 2016, European Journal of Clinical Microbiology & Infectious Diseases.

[70]  L. Harrison,et al.  Detection of katG and inhA mutations to guide isoniazid and ethionamide use for drug-resistant tuberculosis. , 2016, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[71]  D. Gaspar,et al.  Rifabutin-loaded solid lipid nanoparticles for inhaled antitubercular therapy: Physicochemical and in vitro studies. , 2016, International journal of pharmaceutics.

[72]  P. Hopewell,et al.  Treatment of Tuberculosis. A Historical Perspective. , 2015, Annals of the American Thoracic Society.

[73]  D. Chiappetta,et al.  Nanopolymersomes as potential carriers for rifampicin pulmonary delivery. , 2015, Colloids and surfaces. B, Biointerfaces.

[74]  M. Calderón,et al.  Polymeric soft nanocarriers as smart drug delivery systems: State-of-the-art and future perspectives. , 2015, Biotechnology advances.

[75]  Y. Coovadia,et al.  Primary Capreomycin Resistance Is Common and Associated With Early Mortality in Patients With Extensively Drug-Resistant Tuberculosis in KwaZulu-Natal, South Africa , 2015, Journal of acquired immune deficiency syndromes.

[76]  A. Harries,et al.  Diabetes mellitus and tuberculosis: programmatic management issues , 2015, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[77]  R. Jarmin,et al.  Mistaking primary hepatic tuberculosis for malignancy: Could surgery have been avoided? , 2015 .

[78]  I. Kaur,et al.  Nano-formulation of rifampicin with enhanced bioavailability: development, characterization and in-vivo safety. , 2015, International journal of pharmaceutics.

[79]  B. Prasanthi,et al.  Formulation and Characterization of Pyrazinamide Polymeric Nanoparticles for Pulmonary Tuberculosis: Efficiency for Alveolar Macrophage Targeting , 2015, Indian journal of pharmaceutical sciences.

[80]  M. Pai.  The End TB Strategy: India can blaze the trail , 2015, The Indian journal of medical research.

[81]  L. Jia,et al.  Optimal structural design of mannosylated nanocarriers for macrophage targeting. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[82]  B. Goldstein.  Resistance to rifampicin: a review , 2014, The Journal of Antibiotics.

[83]  C. Vilchèze,et al.  Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: Genes, Mutations, and Causalities , 2014, Microbiology spectrum.

[84]  G. Churchyard,et al.  Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI: Randomized, Placebo-Controlled Phase II Clinical Trial in Patients with Latent Tuberculosis Infection , 2014, PloS one.

[85]  T. Jagielski,et al.  Mutations in the embB Gene and Their Association with Ethambutol Resistance in Multidrug-Resistant Mycobacterium tuberculosis Clinical Isolates from Poland , 2013, BioMed research international.

[86]  A. Christopoulos,et al.  Anticancer chemotherapy combined with anti-tuberculosis treatment: A systematic review , 2013 .

[87]  Parth Malik,et al.  Advances in nanotechnology for diagnosis and treatment of tuberculosis , 2013, Current opinion in pulmonary medicine.

[88]  Yingwei Wang,et al.  Enhanced Immune Response and Protective Effects of Nano-chitosan-based DNA Vaccine Encoding T Cell Epitopes of Esat-6 and FL against Mycobacterium Tuberculosis Infection , 2013, PloS one.

[89]  Parissa Farnia,et al.  The totally drug resistant tuberculosis (TDR-TB). , 2013, International journal of clinical and experimental medicine.

[90]  S. Mundayoor,et al.  Vaccine delivery system for tuberculosis based on nano-sized hepatitis B virus core protein particles , 2013, International journal of nanomedicine.

[91]  S. Kalra,et al.  Diabetes and tuberculosis: a review of the role of optimal glycemic control , 2012, Journal of Diabetes & Metabolic Disorders.

[92]  P. Brennan,et al.  A Common Mechanism of Inhibition of the Mycobacterium tuberculosis Mycolic Acid Biosynthetic Pathway by Isoxyl and Thiacetazone* , 2012, The Journal of Biological Chemistry.

[93]  S. Arya,et al.  Emergence of totally drug-resistant tuberculosis: obscure and overlooked issues. , 2012, The International Journal of Tuberculosis and Lung Disease.

[94]  Jeffrey I. Zink,et al.  Targeted Intracellular Delivery of Antituberculosis Drugs to Mycobacterium tuberculosis-Infected Macrophages via Functionalized Mesoporous Silica Nanoparticles , 2012, Antimicrobial Agents and Chemotherapy.

[95]  H. Steel,et al.  Clofazimine: current status and future prospects. , 2012, The Journal of antimicrobial chemotherapy.

[96]  Caragh S Murphy,et al.  Polymeric emulsion and crosslink-mediated synthesis of super-stable nanoparticles as sustained-release anti-tuberculosis drug carriers. , 2011, Colloids and surfaces. B, Biointerfaces.

[97]  S. Worakhunpiset,et al.  gyrA and gyrB mutations in ofloxacin-resistant Mycobacterium tuberculosis clinical isolates in Thailand. , 2011, Southeast Asian Journal of Tropical Medicine and Public Health.

[98]  Stewart T. Cole,et al.  Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis , 2009, Science.

[99]  R. Pandey,et al.  Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential. , 2006, The Indian journal of chest diseases & allied sciences.

[100]  C. Thompson,et al.  Foundations of antibiotic resistance in bacterial physiology: the mycobacterial paradigm. , 2006, Trends in microbiology.

[101]  L. Chauhan,et al.  Revised national TB control programme in India. , 2005, Tuberculosis.

[102]  C. Dye,et al.  Can DOTS control multidrug-resistant tuberculosis? , 2005, The Lancet.

[103]  Anjali Sharma,et al.  Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. , 2004, The Journal of antimicrobial chemotherapy.

[104]  F. Mechaï,et al.  Tuberculous meningitis: Challenges in diagnosis and management. , 2019, Revue neurologique.

[105]  A. Banik,et al.  Prevalence and first-line drug sensitivity trends of Mycobacterium tuberculosis at a tertiary center in North-East India , 2018 .

[106]  K. Yu,et al.  Safety, tolerability and pharmacokinetics of 21 day multiple oral administration of a new oxazolidinone antibiotic, LCB01-0371, in healthy male subjects , 2018, The Journal of antimicrobial chemotherapy.

[107]  Yulia D Isaeva,et al.  Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin. , 2013, Journal of medical microbiology.

[108]  R. Mahajan.  Bedaquiline: First FDA-approved tuberculosis drug in 40 years , 2013, International journal of applied & basic medical research.

[109]  S. Balasubramanian,et al.  Synthesis of biodegradable polymeric nanoparticles and their controlled drug delivery for tuberculosis. , 2011, Journal of biomedical nanotechnology.

[110]  R. Ruslami,et al.  Chapter 20: Diabetes Mellitus and Tuberculosis Treatment , 2011 .